Pasithea Therapeutics Corp.
About
0.72USD+0.02 +2.89%
Closed • Updated at 06:32 GMT+00:00Market Cap$23.90M
Volume1.55M
Beta11.16
RSI44.45
Pasithea Therapeutics Corp. — investor relations, events, news, and company updates on 6ix.
Latest News
May 4 2026
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Apr 20 2026
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Apr 1 2026
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Feb 17 2026
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Jan 13 2026
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Recent Videos
2025-11-28 09:01:37 KTTA Level 2 and Time & Sales
May 10, 2026
KTTA STOCK : POTENTIAL BOUNCEBACK | PASITHEA THERAPEUTICS STOCK
Dec 30, 2025
SHARP SWING | $KTTA STOCK ANALYSIS | PASITHEA THERAPEUTICS STOCK
Dec 02, 2025
파시테라 테라퓨틱스 Pasithea Therapeutics (KTTA) 과학 대 주식
Dec 01, 2025
Community Chat
Ask AI
Try asking